Trial reportBMC complementary medicine and therapies2026
Patterns of complementary and alternative medicine use and factors influencing its utilization in thyroid cancer: findings from the MASTER study.
Trial report in BMC complementary medicine and therapies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundComplementary and alternative medicine (CAM) therapies are increasingly popular; however, comprehensive data on their usage patterns and types remain limited, especially in South Korea. We investigated the patterns and economic impact of CAM use in thyroid cancer after lobectomy.
methodsWe utilized data from the MASTER study, a prospective, multicenter, randomized, controlled trial on patients with differentiated thyroid cancer post-lobectomy. Data on CAM usage in 1,166 patients at baseline and at 3, 6, and 12 months postoperatively were included. Logistic regression quantified the effect of levothyroxine treatment on CAM usage.
resultsCAM use was reported by 58% of participants. Dietary nutritional products were the most used CAM modality, with usage rates of 42.5% at baseline, decreasing to 37.7% at 12 months. Exercise and physical therapies also showed significant differences, with 19.2% using these modalities at baseline, increasing to 27.1% at 12 months. The median cost for CAM varied, with dietary products consistently costing 144 USD (200,000 KRW) and exercise costs rising from 144 USD (200,000 KRW) to 288 USD (400,000 KRW) over time. Patients on levothyroxine were less likely to use CAM, with an odds ratio (OR) of 0.57 (95% confidence interval [CI] = 0.45-0.72, P < 0.001). However, levothyroxine users who did use CAM were more likely to use multiple CAM modalities, with an OR of 3.66 (95% CI = 1.88-7.14, P = 0.001) at baseline, though this association did not remain significant later.
conclusionsCAM is integrated into thyroid cancer treatment, indicating a need for healthcare professionals to discuss its safety and effective care integration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.